Jump to Main Content
Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014
- Naziri, Hamed, Baesi, Kazem, Moradi, Abdolvahab, Aghasadeghi, Mohammad R., Tabarraei, Alijan, McFarland, Willi, Davarpanah, Mohamad Ali
- Archives of virology 2016 v.161 no.9 pp. 2503-2509
- HIV infections, Human immunodeficiency virus, RNA-directed DNA polymerase, antiretroviral agents, drug resistance, drugs, genes, monitoring, mutation, nucleosides, patients, proteinase inhibitors, proteinases, therapeutics, Iran
- Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited. In this study, we aimed to identify HIV drug-resistance-associated mutations in 40 drug-naïve patients and 62 patients under antiretroviral therapy (ART) referred to the Shiraz HIV/AIDS Research Center – the first such data available for the south of Iran. HIV reverse transcriptase and protease genes were amplified and sequenced to determine subtypes and antiretroviral- resistance-associated mutations (RAMs). Subtype CRF35-AD recombinant was the most prevalent in all patients (98 of 102, 96 %), followed by subtype A1, and subtype B (one each, 2 %). Among the 40 ART-naïve patients, two mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance (two with Y115F and T215I) and three associated with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (two with G190S and Y181C, four with V179T) were found. Among ART-experienced patients, four mutations associated with resistance to NRTI, four with NNRTI, and five with protease inhibitors (PI) were found. Twenty patients with high levels of resistance were already on second-line therapy. We document for the first time in this region of Iran high levels of ART resistance to multiple drugs. Our findings call for more vigilant systematic ART resistance surveillance, increased resistance testing, careful management of patients with existing regimens, and strong advocacy for expansion of available drugs in Iran.